Environmental carcinogens, such as polycyclic aromatic hydrocarbons (PAHs), require metabolic activation to DNA-reactive metabolites in order to exert their tumorigenic effects. Benzo 
Introduction
Polycyclic aromatic hydrocarbons (PAHs 1 ) are ubiquitous environmental pollutants. They are formed through the combustion of coal, oil, gas, wood, garbage, or other organic substances, including tobacco and charbroiled meat (1) (2) (3) (4) . Exposure to PAHs occurs primarily through environmental pollutants including mainstream and sidestream smoke, as well as car exhaust emissions (5) . In smokers, B[a]P levels range from 0.5 to 7.8 µg/100 cigarettes when exposure is from mainstream smoke and from 2.5 to 19.9 µg/100 cigarettes from side-stream smoke (6) . Nonsmokers are exposed to PAHs through passive smoking, although at much lower levels of 0.003 to 0.760 µg/m 3 (6) . In addition, both smokers and nonsmokers are exposed to PAHs through the diet and indoor/outdoor air (5, 7, 8) . PAHs reaching the lung and the systemic circulation can be activated to reactive metabolites (7, 8) , which are detoxified and excreted from the body (9, 10) . However, when the detoxification pathways are saturated (11) , the reactive metabolites can directly and covalently modify DNA to form DNA-adducts or produce reactive oxygen species that cause oxidative DNA damage (4, 12) . There is substantial evidence to suggest that PAHs are causative agents in lung (13, 14) , skin (15, 16) , and bladder cancers (15, 16) . Numerous previous reports have linked B[a]P exposure with DNA-adduct formation, which then results in genetic alterations that contribute to the development of multistage carcinogenesis. For example, B[a]P-adduct formation has been shown to inactivate the tumor suppressor, p53, by covalent DNA-adduct formation on guanine bases in the DNA-binding domain (17) .
Several pathways of B[a]P activation are known to be important (4) . However, P4501A1/1B1-mediated activation is the most widely accepted pathway for the formation of B[a]Pderived DNA-adducts (4) . B[a]P is oxidized initially by P4501A1/1B1, to B[a]P-7,8-oxide, which undergoes epoxide hydrolase (EH)-mediated hydrolysis to the proximate carcinogen (-)-B[a]P-7,8-dihydro-7,8-diol (B[a]P-7,8-dihydrodiol) (7, 8) . P4501A1 and 1B1 are considered to be the major P450s involved in the activation of B[a]P (18, 19) . Other human P450s (including P450s 1A2, 2E1, and 3A4) have very low or undetectable activities toward the formation B[a]P-7,8-dihydrodiol (18) . Further activation of (-)-B[a]P-7,8-dihydrodiol occurs through P4501A1/1B1-mediated metabolism to (+)-B[a]PDE, the ultimate carcinogenic reactive metabolite (20) . Other isoforms, including P4501A2, are able to metabolize B[a]P-7,8-dihydrodiol to B[a]PDE to a lesser degree (20) . (+)-B[a]PDE can be detoxified through glutathione S-transferase (GST)-mediated GSH-adduct formation (21, 22) or through further hydrolysis to the corresponding tetraols (23) . B[a]PDE that escapes detoxification reacts with DNA to form adducts, primarily at the exocyclic N 2 -amine of dGuo (24) . In our previous study, H358 lung cells were treated with (()- These studies revealed that (+)-B[a]PDE-dGuo was the major adduct and that in contrast to liver cells, its formation was maximal in H358 lung cells that had not been induced with TCDD (Scheme 1) (4).
In order to further elucidate the mechanism underlying this paradoxical effect, we have conducted experiments to examine the dose-response of DNA-adduct formation to (-)- (24, 25) . Ammonium acetate and formic acid were HPLC grade, and the methanol was Optima grade (Fisher Scientific, Waltham, MA). All water was purified through a Milli-Q reverse osmosis system (Millipore, Billerica, MA).
Preparation of Authentic (()-B[a]PDE-GSH-Adducts.
The GSH-adducts were prepared by a modification of the method described previously (25) . Briefly, (()-B[a]PDE (200 µg) was incubated for 1 h with equine GST (100 units) and GSH (4 mM) in 100 mM potassium phosphate buffer (pH 6.5) at 37°C. The (-)-B[a]PDE-GSH-adduct eluted at an earlier retention time than the (+)-B[a]PDE-GSH-adduct on the YMC ODS-AQ column under the conditions described below. This is similar to the elution profile described previously (26) . Product ion spectra from collisioninduced dissociation (CID) of m/z 610 (B[a]PDE-GSH, MH + ) were essentially identical for the two enantiomers: m/z 592 (MH
Cell Culture. Human bronchoalveolar H358 cells (ATCC #CRL-5807) were maintained in RPMI 1640 nutrient mixture with 10% heat-inactivated FBS, 2 mM L-glutamine, 100 units/mL penicillin, and 100 µg/mL streptomycin. Human liver carcinoma HepG2 cells (ATCC #HB-8065) were maintained in Eagle's Minimum Essential Medium with 10% heat-inactivated FBS, 100 units/mL penicillin, and 100 µg/mL streptomycin. Cells were incubated at 37°C in a humidified atmosphere containing 5% CO 2 and were passaged every 3 days at a 1:3 dilution. Cultured cells with a passage number of 15 or less were used in the experiments to reduce variability during cell culture. 4 OAc buffer containing 0.02% formic acid as mobile phase A and methanol as mobile phase B at a flow rate of 200 µL/min. The gradient started from 49% B to 51% B in 20 min, followed by 51% B to 65% B in 10 min, and continued to 100% B in 5 min. The following mass spectrometer parameters were set: collision gas (nitrogen), 10 units; curtain gas Data for (-)-B[a]P-7,8-dihydrodiol were also acquired using the instrumentation described above. The HPLC method employed a Phenomenex Luna C18(2)-ODS column (4.0 mm I.D. × 125 mm, 4 µm) using 5 mM NH 4 OAc buffer containing 0.1% formic acid as mobile phase A and methanol containing 0.1% formic acid as mobile phase B at a flow rate of 300 µL/min. The gradient started from 60% B to 70% B in 20 min, followed by 70% B to 80% B in 10 min. This was held for 20 min followed by an increase to 95% B in 5 min. Again, this was held for 5 min before returning to starting 60% B, held for 20 min for column equilibration. Mass spectrometer parameters different from those used for (+)-B[a]PDEdGuo adducts were collision gas, 9 units; curtain gas, 10 units; ion source gas number 2, 50 units; entrance potential, 12 V; collision energy, 30 eV; and collision cell exit potential, 20 V. The following transitions were monitored:
Data for the B[a]PDE-GSH-adduct were acquired using a Waters 2690 HPLC system (Waters Co., Milford, MA) equipped with an autosampler and a Thermo Fisher LTQ ion trap mass spectrometer (Thermo Fisher, Mullica Hill, NJ). The HPLC method employed a YMC ODS-AQ column (2.0 mm I.D. × 150 mm, 3 µm) using water containing 0.1% formic acid as mobile phase A and acetonitrile containing 0.1% formic acid as mobile phase B at a flow rate of 200 µL/min. The gradient started from 20% B to 50% B in 8 min, followed by 50% B to 100% B in 14 min; 100% B was held for 3 min followed by a return to starting conditions, 20% B for 10 min. The following mass spectrometer parameters were set: nitrogen was used for sheath (41 units) and auxiliary gas (12 units). Helium was used as the collision gas with a collision energy of 35 eV. All analyses, full scans, product ion scans, and MRM were conducted in positive ESI mode. 48 and 24 h, respectively. After the allotted treatment times, total RNA was extracted from H358 cells using the miRNeasy protocol from Qiagen. Microarray analysis was performed according to the Affymetrix protocol using the Affymetrix HuGene 1.0 array platform (Santa Clara, CA). Four samples from each treatment category were chosen for microarray analysis. Data analysis was performed using Partek Genomics Suite (Partek Inc., St. Louis, MO). Subsequent visualization and filtering used Spotfire DecisionSite, version 9.1 (Tibco Software Inc., Palo Alto, CA, USA). Affymetrix .cel files were imported, and Robust Multiarray Average was performed on the microarray data yielding log 2 transformed signal intensities for each probeset on each array. Next, the low expression probesets were filtered out, retaining probesets with log 2 intensities of greater than 5 in at least 3 -dGuo were used to make standard mixtures of different concentrations (0.1, 0.2, 0.5, 1.0, 2.5, 5.0, and 10.0 ng of each). The standard solutions underwent the same sample preparation and analytical procedures as the experimental samples described above. Calibration curves were calculated with a linear regression analysis of the peak area ratios of standard versus the internal standard. DNA-adduct levels were calculated by interpolation from the calibration curve and normalized with the total base content in each sample (4) . Levels are reported as number of (+)-B[a]PDE-dGuo adducts per 10 6 normal bases. DNA Base Analysis. LC-UV chromatography for DNA base analysis was conducted on a Hitachi Elite Lachrom HPLC system equipped with a UV detector. The separation employed a Phenomenex Luna C18(2) column (4.0 mm I.D. × 125 mm, 5 µm). Solvent A was aqueous 5 mM NH 4 OAc with 0.02% formic acid, and solvent B was methanol. The flow rate was 0.9 mL/min, and DNA bases were separated isocratically at 15% B for 20 min. The UV detector monitored the absorbance at 260 nm. For calibration curves, solutions containing certain concentrations of authentic DNA bases (0.0, 2.0, 5.0, 10.0, 20.0, and 50.0 µg/mL) were subjected to HPLC-UV analysis. The injection volume was 20 µL. Calibration curves were calculated with a linear regression analysis of the peak areas of authentic standards. A portion of the digested sample was subjected to the same HPLC-UV procedure for base analysis. The DNA base level was calculated by interpolation from the calibration curve.
GST Activity Assay. The activity of total GST was assessed in TCDD-induced and noninduced H358 and HepG2 cells using 1-chloro,2,4-dinitrobenzene (CDNB). Induced H358 and HepG2 cells were treated with 10 nM TCDD for 24 h. Briefly, 0.1 M KH 2 PO 4 , pH 6.5, 1.0 mM CDNB, 1.0 mM GSH-, and either GSTR-1 (1 µg) or cell lysate (25 µL) were then combined. Total GST activity was assessed by monitoring CDNB-GSH-adduct formation at 340 nm over 15 min, during which time adduct formation was linear. Activity is reported in nmol/min/mg protein, and nonenzymatic GSH-adduct formation was taken into account by quantifying CDNB-GSH adduct formation in controls that included everything except the enzyme. (Figure 1) ), which was rigorously determined in our previous study (24) . The TCDD caused a significant decrease in (+)-B[a]PDE-dGuo adducts at each concentration of (-)-B[a]P-7,8-dihydrodiol that was used. There was almost a 7-fold decrease of (+)-B[a]PDE-dGuo adducts at 2 µM (-)-B[a]P-7,8-dihydrodiol, the highest concentration that was examined (Figure 1 ). There was also significant up-regulation (p < 0.05) of GSTM1 (1.3-fold), ALDH3A1 (2-fold), and ALDH1A3 (2.8-fold). The increase in CYP1A1 mRNA detected by the microarray experiments was validated by quantitative PCR using CYP1A2 as a negative control (data not shown).
Results
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( Figure 7B ) were identical to the spectra from synthesized standards (data not shown).
LC-MRM/MS analyses conducted over a 6 h period revealed that intracellular and extracellular (-)-B[a]PDE-GSH-adducts
were an order of magnitude higher at all time points in the TCDD-induced H358 lung cells ( Figure 8A and B) when compared with that in the noninduced cells ( Figure 9A and B) . 
Figure 6. LC-MS/MS analysis of B[a]PDE-GSH-adducts in (()-B[a]PDE-treated H358 cells. (A) LC-MS/MS chromatogram of the intracellular (-)-B[a]PDE-GSH-adduct in TCDD-induced H358 cells after a 4 h incubation. (B) Product ion spectrum of the (-)-B[a]PDE-GSH-adduct (MH + , m/z 610) in TCDD-induced H358 cells. (C) LC-MS/MS chromatogram of the intracellular (-)-B[a]PDE-GSH-adduct in noninduced H358 cells after a 4 h incubation. H358 cells pretreated with 10 nM TCDD for 24 h had increased levels of (-)-B[a]PDE-GSH-adducts.
of magnitude increase of both intracellular and extracellular B[a]PDE-GSH-adducts in the H358 lung cells ( Figure 8A and B) when compared with that in HepG2 liver cells ( Figure 8C and D). To confirm that these changes were a result of alterations in GSTs rather than modifications in GSH biosynthesis and utilization, the GSH/GSSG ratio was quantified by stable isotope dilution LC-MS (27) . This ratio did not change significantly in H358 control cells versus TCDD-induced cells, and GSH concentrations did not change ( Supporting Information, Figure 1) .
GST Activity Assay. The overall activity of GSTs was assessed in TCDD-induced and noninduced H358 and HepG2 cells. The GST activity increased modestly in H358 cells treated with 10 nM TCDD for 24 h (Table 1 ). In contrast, the GST activity in HepG2 cells was slightly lower than that found in H358 cells and was further reduced by TCDD treatment (Table  1) .
Discussion
DNA-and GSH-adduct formation was assessed in the H358 human bronchoalveolar cell line because they are known to have basal levels of CYPs and AKRs without induction and are a well-characterized cell model for B[a]P metabolism in the lung (23-25, 28, 29) . Similar studies were conducted in the HepG2 cell line because it has previously been employed extensively as a model for B[a]P metabolism in the liver (30) (31) (32) (33) . Previous studies by our group showed that (+)-B[a]PDE-dGuo adducts were found in higher concentration in H358 parental cells not treated with TCDD to induce P450 expression than in the corresponding TCDD-induced cells (4) . To confirm these data, we examined how the concentration of (-)-B[a]P-7,8-dihydrodiol affected the formation of (+)-B[a]PDE-dGuo in H358 cells. At both low and high concentrations of (-)-B[a]P-7,8-dihydrodiol, there was an increase in DNA-adducts formed in H358 cells when compared with that in TCDD-induced cells (Figure 1) . The TCDD-induced cells metabolized the (-)-B[a]P-7,8-dihydrodiol more rapidly than the noninduced cells so that it could still be detected by LC-MRM/MS in the noninduced cells after a 6 h incubation (Figure 2) . Furthermore, there was a dose-response in the ability of TCDD to reduce B[a]PDEdGuo formation (Figure 3) .
Data obtained in lung cells greatly contrasts with that obtained in liver cells, where there was a significant increase in DNAadducts after TCDD treatment (34) . The effect of TCDD has been ascribed to the up-regulation of P4501A1/1B1 (35) (36) (37) (38) . Therefore, our findings raised the intriguing possibility that TCDD-induction (39) (18, 20) .
In order to gain further insight into gene regulation, a microarray analysis was performed in H358 cells that had been treated with TCDD and or (-)-B[a]P-7,8-dihydrodiol. TCDD was found previously to induce 8 genes (CYP1A1, CYP1B1, CRYZ, GSTM1, GLRX, ALDH3, ALDH1A3, and ALDH10) in human A549 and HPL1A lung cells through the aryl hydrocarbon receptor (AhR) pathway (40) . As was found with A549 and HPLA1 lung cells, CYP1A1 was the major gene that was up-regulated by TCDD in the H358 cells, followed by CYP1B1 (Figure 4 ). We found that there was also significant up-regulation of GSTM1, ALDH3A1, and ALDH1A3. However, in contrast to the A549 and HPLA1 cells (40) , upregulation of CRYZ, GLRX, ALDH10 was not detected in the H358 cells. TCDD binds to the AhR, a cytosolic, ligand activated transcription factor. The AhR is complexed with chaperone proteins, including p23, XAP2/ARA9, and Hsp90 (41, 42) . When TCDD binds to the AhR, a conformational change occurs, which results in the loss of certain chaperone proteins and nuclear localization (37) . Once the TCDD-bound AhR has translocated to the nucleus, it binds with the AhR nuclear translocater. This complex then binds to consensus nucleotide sequences, termed xenobiotic response elements (XREs), in the 5′ untranslated region of responsive genes and modulates the transcription of these genes. inducing P450 expression through the pathway described above for TCDD. In order to confirm this protective effect, direct B[a]PDE-mediated DNA-adduct formation was examined in the TCDD-induced and noninduced H358 cells. This showed that (+)-B[a]PDE-dGuo adducts were significantly reduced in the TCDD-treated H358 cells when compared with those in the noninduced cells ( Figure 5 ).
The most logical explanation for the TCDD effect on DNAadduct formation is that increased metabolism of (+)-B[a]PDE had occurred. It has recently been recognized that TCDD can up-regulate GSTs in rodent cells (43) . If this occurred in human lung cells, it could result in increased conversion of (+)- Figure 7C ) also occurred, but levels were much lower than that in H358 cells ( Figure 7A ). GSH-adducts once secreted by cells are metabolized to their corresponding cysteinylglycine adducts by γ-glutamyltranspeptidase, which is localized on the external surface of the plasma membrane (44, 45) . The loss of the initially formed B[a]P-GSH-adducts over time observed in the H358 and HepG2 cell media (Figures 8 and 9 ) is in keeping with this expected pathway of metabolism. However, the formation of the B[a]P-cysteinylglycine-adducts or their further dipeptidase and N-acetyl-cysteine-transferase-mediated conversion to cysteine (45) and N-acetylcysteine metabolites (46) (26, 48, 49) . GSTR and GSTµ show much lower enantioselectivity for (+)-B[a]PDE, and in addition, GSTµ is primarily expressed in the liver rather than the lung (50, 51) . Previous studies have shown that GSTπ-expressing cell lines are protected against (+)-B[a]PDE-mediated DNA damage (52, 53) . Therefore, it is likely that GSTR and/or GSTµ are responsible for the racemic formation of B[a]PDE-GSH-adducts in the liver-derived HepG2 cells, whereas GSTπ is responsible for enantioselective GSH-adduct formation in the lung-derived H358 cells. Intracellular and extracellular (-)-B[a]PDE-GSHadduct levels in our study were an order of magnitude higher in the TCDD-induced H358 lung cells ( Figure 8A and B) when compared with that in the noninduced cells ( Figure 9A and B) , whereas TCDD induction ( Figure 8C and D) had little effect on the HepG2 liver cells when compared with that in the Figure 8C and D) .
These findings are consistent with lung cell specific TCDDmediated up-regulation of GST isoforms that have enantioselectivity similar to that found for GSTπ-mediated detoxification of (+)-B[a]PDE (26, 48, 49) or induction of a post-translational modification that increases the activity of GSTπ. However, we were unable to detect up-regulation of any GSTs with the required stereoselectivity. It is noteworthy that GSTπ can undergo epidermal growth fact receptor-mediated phosphorylation at Tyrosine-7 and Tyrosine-198 (54) . In addition, GSTπ is phosphorylated by the action of serine/threonine kinases, protein kinase C, and protein kinase A (55). Furthermore, epidermal growth fact receptor-mediated phosphorylation of Tyrosine-7 and Tyrosine-198 was found to increase the activity of GSTπ through a conformational change in the enzyme (54) . Therefore, there is a body of literature to suggest that the substantial increase in GSH-adduct formation we observed could have arisen through a TCDD-mediated increase in the phosphorylation of GSTπ with a concomitant increase in its activity.
Total GST activity was quantified using the CDNB conjugation assay to assess the level of all GSTs present in H358 and HepG2 cells. The method was used previously to compare GST expression between lung and liver cells (56) . A modest increase in total GST levels was observed in TCDD-induced H358 cells, whereas a significant decrease in GST activity was observed in TCDD-induced HepG2 cells (Table 1) . Dostal et al. have reported that the highest affinity for CDNB is GSTR (21) , further suggesting that this GST isoform is not an important mediator of B[a]PDE-GSH-adduct formation. It is noteworthy that a recent study was unable to detect any GSH-derived adducts of B[a]PDE in primary human hepatocytes (46) . However, B[a]PDE-GSH-adducts were not analyzed directly, but the corresponding N-acetyl-cysteine-adducts were employed as surrogate biomarkers of GSH-adduct formation. The formation of Nacetylcysteine-adducts requires γ-glutamyltransferase-mediated conversion of the GSH-adducts into cysteinylglycine-adducts, followed by dipeptidase hydrolysis to the cysteine-adducts, and subsequent N-acetyl transferase-mediated acetylation (45) . Therefore, it is conceivable that the resulting B[a]PDE-Nacetylcysteine-adducts were not formed in sufficient quantities by this complex metabolic pathway in order to permit their detection.
In summary, TCDD-induction of P4501A1/1B1 in lung cells would be predicted to increase the activation of (-) . TCDD did not cause any changes in GSH or GSSG levels (Supporting Information, Figure 1 ). This suggests that the increased GSH-adduct formation most likely occurred through up-regulation of a GST with high enantioselectivity for (+)-B[a]PDE detoxification (26, 48, 49) . Therefore, our data provide compelling evidence that TCDD can induce the metabolism of (+)-B[a]PDE to a nongenotoxic GSH-adduct in lung-derived H358 cells most likely through an AhR-dependent pathway (Scheme 2). It has been proposed that TCDD/AhR-mediated induction of antioxidant response element (ARE) driven genes such as GSTs can occur in rodent models through the Nrf2-Keap1 pathway (43) . However, there is no evidence that human GSTs possess AREs in their noncoding region, and therefore, it seems unlikely that this mechanism can explain our findings. Unfortunately, the majority of GST induction studies have been conducted in rodent cells (43, 57) , and therefore, the ability of TCDD to regulate the activity of GSTs in human cells will clearly require substantial additional studies. It will also be necessary to confirm that our findings can be observed in other human lung derived cells. However, to our knowledge, this is the first report that TCDD can induce GSH-adduct formation in human lung cells and therefore provides a useful model system with which to pursue further studies.
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